{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000070","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.783996+00:00","generated_at":"2026-06-01T06:52:09.116608+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus presents FELIX update: 78% ORR, 40% ongoing remission without SCT, median OS 23.8 months","bullets":["ORR 78% (99/127); median EFS 11.9 months, median OS 23.8 months; 12-month OS rate 61.1%.","40% of responders in ongoing remission without SCT or other therapy at median 21.3 months follow-up.","Ongoing CAR T persistence associated with 2.7x lower relapse/death risk vs. loss of persistence.","Consolidative SCT after obe-cel did not appear to improve EFS or OS in responders.","BLA under FDA review with PDUFA target action date November 16, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000070","json":"https://secwatch.observer/filing/0001730463-24-000070.json","markdown":"https://secwatch.observer/filing/0001730463-24-000070.md","text":"https://secwatch.observer/filing/0001730463-24-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000070/0001730463-24-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000070/autl-20240531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:52:09.116608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}